Copyright Reports & Markets. All rights reserved.

Global Group A and C Meningococcal Polysaccharide Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Polysaccharide Vaccine
    • 1.3.3 Polysaccharide-protein Conjugate Vaccine
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Centers for Disease Control and Prevention
    • 1.4.4 Others
  • 1.5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size & Forecast
    • 1.5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Sanofi Pasteur
    • 2.2.1 Sanofi Pasteur Details
    • 2.2.2 Sanofi Pasteur Major Business
    • 2.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Pasteur Recent Developments/Updates
  • 2.3 GlaxoSmithKline
    • 2.3.1 GlaxoSmithKline Details
    • 2.3.2 GlaxoSmithKline Major Business
    • 2.3.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.3.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GlaxoSmithKline Recent Developments/Updates
  • 2.4 Merck & Co.
    • 2.4.1 Merck & Co. Details
    • 2.4.2 Merck & Co. Major Business
    • 2.4.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.4.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Merck & Co. Recent Developments/Updates
  • 2.5 Royal (Wuxi) Bio-Pharmaceutical
    • 2.5.1 Royal (Wuxi) Bio-Pharmaceutical Details
    • 2.5.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
    • 2.5.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.5.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
  • 2.6 Zhifei Biological
    • 2.6.1 Zhifei Biological Details
    • 2.6.2 Zhifei Biological Major Business
    • 2.6.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.6.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Zhifei Biological Recent Developments/Updates
  • 2.7 Toyouvax
    • 2.7.1 Toyouvax Details
    • 2.7.2 Toyouvax Major Business
    • 2.7.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.7.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Toyouvax Recent Developments/Updates
  • 2.8 Walvax
    • 2.8.1 Walvax Details
    • 2.8.2 Walvax Major Business
    • 2.8.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.8.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Walvax Recent Developments/Updates
  • 2.9 AIM Bio
    • 2.9.1 AIM Bio Details
    • 2.9.2 AIM Bio Major Business
    • 2.9.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.9.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 AIM Bio Recent Developments/Updates
  • 2.10 Lanzhou Institute of Biological Products
    • 2.10.1 Lanzhou Institute of Biological Products Details
    • 2.10.2 Lanzhou Institute of Biological Products Major Business
    • 2.10.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.10.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Lanzhou Institute of Biological Products Recent Developments/Updates
  • 2.11 Cansino Biologics
    • 2.11.1 Cansino Biologics Details
    • 2.11.2 Cansino Biologics Major Business
    • 2.11.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.11.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Cansino Biologics Recent Developments/Updates
  • 2.12 Chengda Biotechnology
    • 2.12.1 Chengda Biotechnology Details
    • 2.12.2 Chengda Biotechnology Major Business
    • 2.12.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.12.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Chengda Biotechnology Recent Developments/Updates
  • 2.13 Sinovac
    • 2.13.1 Sinovac Details
    • 2.13.2 Sinovac Major Business
    • 2.13.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product and Services
    • 2.13.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Sinovac Recent Developments/Updates

3 Competitive Environment: Group A and C Meningococcal Polysaccharide Vaccine by Manufacturer

  • 3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Group A and C Meningococcal Polysaccharide Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Group A and C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Group A and C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2025
  • 3.5 Group A and C Meningococcal Polysaccharide Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Group A and C Meningococcal Polysaccharide Vaccine Market: Region Footprint
    • 3.5.2 Group A and C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
    • 3.5.3 Group A and C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region
    • 4.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021-2032)
  • 4.5 South America Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
    • 7.3.1 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
    • 8.3.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
    • 10.3.1 South America Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Group A and C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Group A and C Meningococcal Polysaccharide Vaccine Market Drivers
  • 12.2 Group A and C Meningococcal Polysaccharide Vaccine Market Restraints
  • 12.3 Group A and C Meningococcal Polysaccharide Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Group A and C Meningococcal Polysaccharide Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Group A and C Meningococcal Polysaccharide Vaccine
  • 13.3 Group A and C Meningococcal Polysaccharide Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Group A and C Meningococcal Polysaccharide Vaccine Typical Distributors
  • 14.3 Group A and C Meningococcal Polysaccharide Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Group A and C Meningococcal Polysaccharide Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Group A and C Meningococcal Polysaccharide Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Group A and C Meningococcal Polysaccharide Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Dose), and average selling prices (US$/Dose), 2021-2032
    Global Group A and C Meningococcal Polysaccharide Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Dose), and average selling prices (US$/Dose), 2021-2032
    Global Group A and C Meningococcal Polysaccharide Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Dose), and average selling prices (US$/Dose), 2021-2032
    Global Group A and C Meningococcal Polysaccharide Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Group A and C Meningococcal Polysaccharide Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Group A and C Meningococcal Polysaccharide Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biological, Toyouvax, Walvax, AIM Bio, Lanzhou Institute of Biological Products, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Group A and C Meningococcal Polysaccharide Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Polysaccharide Vaccine
    Polysaccharide-protein Conjugate Vaccine
    Market segment by Application
    Hospital
    Centers for Disease Control and Prevention
    Others
    Major players covered
    Pfizer
    Sanofi Pasteur
    GlaxoSmithKline
    Merck & Co.
    Royal (Wuxi) Bio-Pharmaceutical
    Zhifei Biological
    Toyouvax
    Walvax
    AIM Bio
    Lanzhou Institute of Biological Products
    Cansino Biologics
    Chengda Biotechnology
    Sinovac
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Group A and C Meningococcal Polysaccharide Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Group A and C Meningococcal Polysaccharide Vaccine, with price, sales quantity, revenue, and global market share of Group A and C Meningococcal Polysaccharide Vaccine from 2021 to 2026.
    Chapter 3, the Group A and C Meningococcal Polysaccharide Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Group A and C Meningococcal Polysaccharide Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Group A and C Meningococcal Polysaccharide Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Group A and C Meningococcal Polysaccharide Vaccine.
    Chapter 14 and 15, to describe Group A and C Meningococcal Polysaccharide Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now